EN DE
Watch Sinopharm Tech Holdings Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sinopharm Tech Holdings Ltd (8156) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Sinopharm Tech Holdings Ltd stock HK$0.11, price HK$0.15, that is 27.8% below the price, quality 39 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Technology HK · ISIN KYG2159V1418

ST Sinopharm Tech Holdings Ltd logo Thin data Nov 10, 2026

Sinopharm Tech Holdings Ltd

8156 · HK
Expensive, weak quality

Our calculation puts a fair price 28% below what the stock costs today.

Negative equity (buybacks among others)
Revenue last quarter 56% below a year ago.
Fair value HK$0.1076 · Overvalued
Quality 39/100
Weak Growth (revenue 5y −10.1 %/yr in HKD)
Loss-making · -20.1% net margin (TTM)
Negative free cash flow
Trails peers (1/7)
Narrow moat 12/100
Thin data
Estimate⚠ Thinly traded
Watch Sinopharm Tech Holdings Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$6.75 HK$0.0710 Fair Value HK$0.1076 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range HK$0.0710 – HK$6.75 · fair‑value band HK$0.0807 – HK$0.1345 · the HK$0.1490 price screens above the HK$0.1076 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow Sinopharm Tech Holdings in your weekly email

Every Wednesday you see whether Sinopharm Tech Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sinopharm Tech Holdings Limited, an investment holding company, engages in trading of medical and related products in China.

Show moreShow less

It is involved in the provision of Internet plus solution services, including provision of internet related solution services; and manufacturing and distribution of personal protective equipment, consumables, and other related goods.

The company also engages in providing supply chain services, including provision of supply chain management, data analysis, and related services; and trading of related goods, and trading of medial and related products.

Sinopharm Tech Holdings Limited was formerly known as China Vanguard You Champion Holdings Limited and changed its name to Sinopharm Tech Holdings Limited in June 2019. The company was founded in 1999 and is based in Central, Hong Kong.

Stock analysis

Sinopharm Tech Holdings Ltd (8156) currently trades at HK$0.1490, while our estimate is HK$0.1076, 28% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$0.0807 (bear) to HK$0.1345 (bull), the price of HK$0.1490 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Technology sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Sinopharm Tech Holdings Ltd reported revenue of HK$45.6M in FY2026 versus HK$41.0M in FY2022, a compound +2.7%/yr. Reported net income was −HK$9.1M in FY2026.

Key figures

Market cap HK$94.4M (≈ $12.0M) Micro · P/S ratio 2.70 · Net margin −20.1% · Return on assets (EBIT) −83.5% (5-year average) · Operating margin −33.7% · Revenue (TTM) HK$45.6M · Revenue growth (YoY) −55.6% · Free cash flow −HK$4.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 57% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Technology peers we cover trades at 9% fair-value upside, at −28%, 8156 screens richer than that median.

Fair Value

Bear HK$0.0807 Fair Value HK$0.1076 Bull HK$0.1345
Price HK$0.1490 · Downside -27.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 38
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 28
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 8
How calm the share price moves, does not count
Price momentum 14
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−25.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.1%
Start year 2021 (pandemic). Over 10 years: +2.8% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−71.8% (2021) → −17.9% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

8156 screens overvalued: fair value 28% below the price. Compare with SAP SE →

Compare Sinopharm Tech Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Software - Application · 719 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −27.8% · Below median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −40.7% · Bottom 25%
Net margin (12 months) −20.1% · Bottom 25%
Operating margin (12 months) −33.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −55.6% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Software - Application median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 2.07× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Software - Application stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Adobe Inc ADBE $237.32 $463.72 +95% vs 8156
Salesforce, Inc CRM $214.94 $342.73 +59% vs 8156
Uber Technologies, Inc UBER $71.17 $101.28 +42% vs 8156
Intuit Inc INTU $338.23 $459.14 +36% vs 8156
ServiceNow, Inc NOW $102.76 $112.17 +9% vs 8156
SAP SE SAP €209.95 €173.59 −17% vs 8156
Cadence Design Systems, Inc CDNS $336.53 $225.48 −33% vs 8156
Automatic Data Processing, Inc ADP $302.06 $150.40 −50% vs 8156
Shopify Inc SHOP $152.06 $64.96 −57% vs 8156
Snowflake Inc SNOW $291.14 $73.81 −75% vs 8156

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sinopharm Tech Holdings Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sinopharm Tech Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8156

Frequently asked questions

Is Sinopharm Tech Holdings Ltd (8156) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$0.1076 versus a price of HK$0.1490, about 28% lower (overvalued).
What is the fair value of 8156?
Our estimate for Sinopharm Tech Holdings Ltd is HK$0.1076 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$0.1490.
What is the quality score of 8156?
Sinopharm Tech Holdings Ltd has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sinopharm Tech Holdings Ltd (8156)?
Our calculated price target is the estimate of HK$0.1076 (as of Nov 10, 2026). Cautious scenario HK$0.0807, optimistic scenario HK$0.1345. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Sinopharm Tech Holdings Ltd stock forecast for 2026?
Our estimate puts fair value at HK$0.1076, about 28% lower versus a price of HK$0.1490 (overvalued). Cautious scenario HK$0.0807, optimistic scenario HK$0.1345. The calculation is refreshed regularly with new filings.
What is the revenue of Sinopharm Tech Holdings Ltd (8156)?
Sinopharm Tech Holdings Ltd reported trailing-twelve-month revenue of about HK$45.6M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Sinopharm Tech Holdings Ltd (8156)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sinopharm Tech Holdings Ltd it is HK$0.1076 per share (as of Nov 10, 2026), against a price of HK$0.1490.
Is Sinopharm Tech Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 8156 trades above its calculated fair value: price HK$0.1490, fair value HK$0.1076, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8156?
No. The price is what the market pays today (HK$0.1490); the fair value is what the company's own numbers justify (HK$0.1076). For Sinopharm Tech Holdings Ltd the two are HK$0.0414 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sinopharm Tech Holdings Ltd worth?
The market values Sinopharm Tech Holdings Ltd at about HK$94.4M (market capitalisation, as of Nov 10, 2026). Per share that is HK$0.1490; our models calculate a fair value of HK$0.1076 per share.
What do the bullish and bearish scenarios say about 8156?
Our models span a range for Sinopharm Tech Holdings Ltd: cautious scenario HK$0.0807, base HK$0.1076, optimistic HK$0.1345 per share (as of Nov 10, 2026, price HK$0.1490). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sinopharm Tech Holdings Ltd (8156)?
Balance-sheet figures for Sinopharm Tech Holdings Ltd (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 8156 from its 52-week high?
Sinopharm Tech Holdings Ltd trades at HK$0.1490, about 57% below its 52-week high of HK$0.3500 and at the low of HK$0.1490 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.1076 is for.
Which stocks are comparable to Sinopharm Tech Holdings Ltd?
From the same area (Technology) we also value SAP SE, Salesforce, Inc, Shopify Inc, ServiceNow, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sinopharm Tech Holdings Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price HK$0.1490, calculated fair value HK$0.1076 (−28%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Sinopharm Tech Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sinopharm Tech Holdings Ltd (8156)?
The closing price on Nov 10, 2026 was HK$0.1490. Our estimate is HK$0.1076, about 28% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sinopharm Tech Holdings Ltd right now?
The price sits above even our optimistic bull case (HK$0.1345). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Sinopharm Tech Holdings Ltd

How large is the market capitalisation of Sinopharm Tech Holdings Ltd (8156)?
The market capitalisation of Sinopharm Tech Holdings Ltd is HK$94.4M (≈ $12.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sinopharm Tech Holdings Ltd (8156)?
The price-to-sales ratio of Sinopharm Tech Holdings Ltd is 2.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Sinopharm Tech Holdings Ltd (8156)?
The net margin of Sinopharm Tech Holdings Ltd is −20.1% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Sinopharm Tech Holdings Ltd (8156)?
On an EBIT basis the return on assets of Sinopharm Tech Holdings Ltd is −83.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sinopharm Tech Holdings Ltd (8156)?
The operating margin of Sinopharm Tech Holdings Ltd is −33.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sinopharm Tech Holdings Ltd (8156)?
Revenue at Sinopharm Tech Holdings Ltd is growing −55.6% versus a year earlier (3y avg +2.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sinopharm Tech Holdings Ltd (8156) generate?
The free cash flow of Sinopharm Tech Holdings Ltd is −HK$4.0M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sinopharm Tech Holdings Ltd (8156) carry?
The net debt of Sinopharm Tech Holdings Ltd is HK$25.1M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Sinopharm Tech Holdings Ltd in the live analysis

One click puts Sinopharm Tech Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.